Andrew J Piper-Vallillo
Overview
Explore the profile of Andrew J Piper-Vallillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Piper-Vallillo A, Mooradian M, Meador C, Yeap B, Peterson J, Sakhi M, et al.
JTO Clin Res Rep
. 2020 Nov;
2(1):100124.
PMID: 33205053
Introduction: Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms,...
12.
Sehgal K, Piper-Vallillo A, Viray H, Khan A, Rangachari D, Costa D
Precis Cancer Med
. 2020 Aug;
3.
PMID: 32776005
-rearranged (also known as fusion-positive) non-small-cell lung cancer is an uncommon but distinct molecular subgroup seen in approximately 1-2% of cases. Oncogene addiction due to constitutive ROS1 tyrosine kinase activation...
13.
Xu W, Piper-Vallillo A, Bindal P, Wischhusen J, Patel J, Costa D, et al.
medRxiv
. 2020 Aug;
PMID: 32743607
Question: What is the median time to clearance of SARS-CoV-2 among cancer patients according to currently used criteria? Findings: In this single-institution retrospective cohort study, the median time to SARS-CoV-2...
14.
Piper-Vallillo A, Sequist L, Piotrowska Z
J Clin Oncol
. 2020 Jun;
:JCO1903123.
PMID: 32552277
Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advanced -mutant non -small cell lung cancer (NSCLC). Understanding osimertinib resistance mechanisms and...